Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/01/26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 05/15/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
5 | |
| 05/14/26 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
  |
112 |
| 05/14/26 | 8-K | Current report |
|
|
10 |
| 05/14/26 | 8-K | Current report |
|
|
59 |
| 05/04/26 | 8-K | Current report |
|
|
116 |
| 05/04/26 | 424B5 | Prospectus [Rule 424(b)(5)] |
|
79 | |
| 05/04/26 | 8-K | Current report |
|
|
4 |
| 04/28/26 | ARS | Annual Report to Security Holders |
|
180 | |
| 04/28/26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 |
